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Summary 
HIV-2 is less pathogenic than HIV-1 and may provide partial cross-protection from HIV-1-
induced pathology. Although both viruses replicate in T cells of infected patients, only HIV-2 
replicates efficiently in dendritic cells (DCs) and activates innate immune pathways. The 
mechanism of innate immune sensing, including the DC sensor, is unknown. Using mutations 
in the viral capsid, we dissociated sensing from productive infection in DCs. Capsid-mutated 
HIV-2 revealed that sensing requires viral cDNA synthesis, but not nuclear entry or genome 
integration. The HIV-1 capsid prevented viral cDNA sensing up to integration, allowing the 
virus to escape innate recognition. In contrast, DCs sensed capsid-mutated HIV-1 and 
enhanced stimulation of T cells in the absence of productive infection. Finally, we found that 
DC sensing of HIV-1 and HIV-2 required the DNA sensor cGAS. Thus, the HIV capsid 
dictates innate sensing of the viral cDNA by cGAS in dendritic cells. This pathway may 
potentially be harnessed to develop effective vaccines. 
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Introduction 
The human immune system mounts an immune response against HIV-1, but this response is 
not protective in most individuals. In contrast, the related lentivirus HIV-2, which is less 
pathogenic than HIV-1, has been proposed to be controlled by the immune system (Rowland-
Jones and Whittle, 2007). Strikingly, co-infection with HIV-1 and HIV-2 results in a better 
outcome than HIV-1 infection alone, including delayed progression to AIDS, suggesting that 
the immune response against HIV-2 induces cross-reactive protection against HIV-1 
pathology (Esbjornsson et al., 2012). A key challenge is thus to understand how the immune 
system differs at its ability to induce immune responses against HIV-1 and HIV-2. 
Dendritic cells (DCs) play a major role in the induction of immune responses. Paralleling the 
pathophysiological differences between the two viruses, DCs differ at their ability to induce 
an innate immune response against HIV-1 and HIV-2 (Manel et al., 2010; Manel and Littman, 
2011). DCs do not normally get activated and efficiently infected by HIV-1 (Granelli-Piperno 
et al., 2004; Manel et al., 2010) while DCs are naturally infected and activated by HIV-2 
(Manel et al., 2010). The absence of DC activation by HIV-1 is in part a consequence of the 
poor ability to infect these cells (Manel et al., 2010), which is imposed by the restriction 
factor SAMHD1 (Hrecka et al., 2011; Laguette et al., 2011), an Aicardi-Goutières Syndrome 
(AGS) susceptibility gene (Rice et al., 2009). In contrast, HIV-2 encodes the small accessory 
protein Vpx, which overcomes the SAMHD1 restriction in DCs. The Vpx protein is 
incorporated into the viral particles and released into the DCs after viral entry where it 
induces degradation of SAMHD1. When HIV-1 is complemented with the Vpx protein, DCs 
become readily infected (Goujon et al., 2006). Infected DCs in turn sense the virus and induce 
a concomitant innate immune response (Manel et al., 2010). In this setting, sensing of HIV-1 
requires genome integration and expression of the viral capsid (Manel et al., 2010; Sunseri et 
al., 2011) and requires interaction between the newly synthesized viral capsid and the cellular 
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prolyl-isomerase Cyclophilin A (CypA) (Luban et al., 1993; Manel et al., 2010). However, 
whether capsid or another viral component is the actual pathogen-associated molecular 
pattern (PAMP) in DCs is not known. Intriguingly, DCs do not sense the reverse-transcribed 
HIV-1 cDNA or the incoming capsid before viral integration occurs, even in the presence of 
Vpx. Whether DCs are competent for sensing HIV-1 before integration occurs or whether 
they lack the sensing machinery remains to be determined. 
Here, we focused on HIV-2 sensing by DCs to identity the mechanism of HIV-1 and HIV-2 
sensing and the DC sensor. 
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Results 
Engineering HIV-2 capsids of variable affinity for CypA to modulate sensing in DCs 
In HIV-1, the interaction of capsid with CypA is required for DC activation (Manel et al., 
2010). We reasoned that altering the capsid-CypA interaction might allow us to gain 
mechanistic insight into sensing by DCs, in particular the natural sensing of HIV-2. We 
noticed that two residues in HIV-1 capsid (His87-Ala88) located in the CypA-binding loop 
(Yoo et al., 1997), align to only one residue in HIV-2 capsid (Pro86) (Figure 1A), which 
binds less efficiently to CypA (Price et al., 2009). In HIV-1, His87-Ala88 position the Pro90, 
the substrate of the isomerizing activity, into the catalytic site of CypA. Strikingly, in the 
aligned capsid of HIV-2, the homologous Pro88 is not positioned correctly in the catalytic site 
of CypA (Figures 1C, 1D). This raised the possibility that introducing His-Ala in place of 
Pro86 in HIV-2 (Figure 1B), would positions Pro88 in the catalytic site and increase the 
affinity of HIV-2 capsid for CypA (HIV-2 affinity-enhanced capsid, HIVac-2), potentially 
perturbing innate sensing by DCs. 
Expression of HIVac-2 was similar to its WT counterpart and the mutation did not alter 
expression of CypA in virus-producing cells (Figure 1E). Examination of particles by 
transmission electron microscopy showed a typical lentiviral ultrastructure (data not shown). 
However, HIVac-2 particles encapsidated 28 times more CypA than HIV-2 WT and 3 times 
more than HIV-1 (Figure 1E and Figure S1A). We measured the binding of recombinant 
capsid proteins (N-terminal domains) to recombinant CypA (Figure S1B, S1C). Using a co-
precipitation assay, HIVac-2 capsid remained better associated to CypA compared to HIV-2 
WT capsid. The association was inhibited by Cyclosporin A, an inhibitor of the capsid-CypA 
interaction that targets the active site of CypA. Next, microscale thermopheresis (MST) was 
used to estimate the dissociation constant between CypA and the capsids. The affinity of 
HIV-2 WT capsid to CypA was too low to be determined in this assay, while the affinity of 
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HIVac-2 capsid to CypA was 2.6 µM  (Figure S1D). Thus, HIVac-2 capsid bound CypA with 
a higher affinity that the HIV-2 WT capsid. 
 
DC sensing of capsid-mutated HIV-2 in the absence of productive infection 
We examined the ability of HIV-2 WT and HIVac-2 to infect and activate DCs. We used a 
single-round HIV-2 vector that expressed GFP in DCs after integration to measure infection. 
Since innate sensing of HIV-1 with Vpx was independent of the viral envelope used (Manel et 
al., 2010), we used VSV-G-pseudotyped particles. As previously shown, HIV-2 WT was able 
to infect and activate DCs (Figure 2A) in a dose-dependent manner (Figure 2B and Figure 
S2A). Strikingly, HIVac-2 infection was completely blocked in DCs (Figure 2A, 2B and 
Figure S2A). Unexpectedly, the block did not prevent DCs sensing of HIVac-2, and HIVac-2 
activated DCs more efficiently than HIV-2 WT (Figure 2B). Addition of Virus-Like Particles 
(VLPs) from the macaque simian immunodeficiency virus (SIV), a close relative of HIV-2, 
which provides an increased amount of Vpx and boosts abrogation of SAMHD1 restriction 
(Hrecka et al., 2011; Laguette et al., 2011), enhanced activation by HIVac-2 but infection was 
still blocked (Figure S2A). DC activation was characterized by production of type I 
interferon (Figure 2C) and the type I IFN response gene IP-10 (CXCL10) (Figure 2D) by the 
DCs (Manel et al., 2010). Neutralizing reagents against type I IFN effectively inhibited 
expression of IP-10, while CD86 expression was less dependent on type I IFN (Figure S2B). 
However, neutralizing type I IFN did not rescue the infection by HIVac-2, indicating an 
intrinsic effect of the mutation. Thus, mutations of the HIV-2 capsid reveal that DCs are 
competent for innate sensing in the absence of productive viral infection. 
 
DC sensing of HIV-2 requires synthesis of the viral cDNA but not integration 
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We dissected the early steps of the viral cycle to identify the determinants of HIV-2 that are 
sensed in DCs (Figure 3A). To determine if the viral genetic material was required for 
sensing, we generated HIV-2 and HIVac-2 VLPs in which encapsidation of the viral genomic 
RNA was reduced (∆Ψ) by combining two previsouly described mutations (Griffin et al., 
2001; Poeschla et al., 1998). The mutation did not prevent Gag maturation in the particles 
(Figure S3A) but reduced viral infectivity (Figure S3B). Despite their residual infectivity, 
HIV-2 and HIVac-2 VLPs with reduced RNA encapsidation were not efficient at activating 
DCs (Figure S3C). Thus, intact encapsidation of the genomic RNA in the particles is required 
for sensing. Next, to determine if viral DNA generated after reverse transcription was 
required for sensing, we generated particles lacking Vpx that are unable to abrogate the 
SAMHD1 restriction (∆Vpx) and are compromised for reverse transcription. HIV-2 and 
HIVac-2 particles lacking Vpx were not infectious and were unable to activate DCs (Figure 
S3D). To confirm that a viral cDNA was required for sensing, we added the reverse 
transcriptase inhibitor AZT at the time of infection. AZT prevented infection and sensing by 
HIV-2 (Figures 3B, 3C). Thus, synthesis of a viral cDNA is required for sensing. We next 
examined if integration was required for sensing by using Raltegravir, an inhibitor of 
integrase. As expected, Raltegravir blocked infection of HIV-2 WT (Figure 3B). However, 
Raltegravir did not prevent DC activation by HIV-2 WT and HIVac-2 (Figures 3B, 3C). To 
confirm that sensing occurred in the absence of integration, we inactivated the integrase (IN) 
by introducing a D116A mutation in its catalytic site in HIV-2 and HIVac-2 (Figure 3A). 
D116A-mutated viral particles displayed a normal profile of mature capsid protein (Figure 
S3A). HIV-2 IN D116A and HIVac-2 IN D116A maintained the ability to activate DCs 
(Figures 3D, 3E). Thus, DCs sense HIV-2 before integration and the viral cDNA is required. 
 
DCs sense HIV-2 in the cytosol 
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Sensing of HIV-2 may occur in the cytosol or in the nucleus. We measured the relative 
abundance of the 'Late RT' HIV-2 cDNA product, the '2LTR circles' (a hallmark of nuclear 
entry of the viral DNA) and the 'integrated' proviral DNA after infection of DCs (Figure 4A). 
HIV-2 WT generated all forms of DNA in an AZT-sensitive manner (Figure 4B). HIVac-2, 
which activates DCs in the absence of infection, produced normal levels of Late RT viral 
cDNA, but no significant levels of 2LTR circles or integrated DNA (Figure 4B, red arrows). 
Treatment of HIV-2 WT with Raltegravir reduced the amount of integrated DNA and also 
increased the levels of 2LTR circles, but this was not the case for HIVac-2. This indicates that 
sensing occurs before the formation of the 2LTR circles, thus presumably in the cytosol. 
Next, we determined if nuclear entry was required for sensing. We mutated the central 
polypurine-tract (cPPT), which is required for nuclear import of the viral cDNA in dendritic 
cells (Riviere et al., 2010; Zennou et al., 2000)  (Figure 4A). The mutation did not modify the 
Gag maturation profile of viral particles, incorporation of CypA and Vpx or efficiency of RT 
(Figures S4A, S4B). We confirmed that the cPPT mutation reduced infectivity of HIV-2 in 
non-dividing DCs (Figure 4C) and the abundance of 2LTR circles (Figure S4B). Sensing of 
cPPT-mutated HIVac-2 and HIV-2 was maintained (Figure 4D). Taken together, these results 
show that sensing requires the cDNA in the cytosol. 
 
The HIV-1 capsid prevents cDNA sensing, escaping innate sensing up to integration 
Unlike HIV-2 or HIVac-2, DCs do not sense the HIV-1 cDNA before integration (Manel et 
al., 2010). We hypothesized that in HIV-1 with Vpx the wild-type capsid masked the viral 
DNA, preventing innate sensing up to integration. To examine if the HIV-1 cDNA can 
stimulate an innate response, we mutated the CypA-binding loop of HIV-1 capsid to the 
corresponding sequence from HIVac-2 (Figure 5A). HIVac-1 particles incorporated more 
CypA (Figures S5A, S5B) and the HIVac-1 capsid had a higher affinity for CypA than wild-
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type HIV-1 (Figures S5C, S5D). Similar to HIVac-2, HIVac-1 retained the ability to activate 
DCs and induce IP-10 in the presence of Vpx and showed a reduced infectivity (Figures 5B, 
5C, 5D). Blockade of residual HIVac-1 integration with Raltegravir did not inhibit innate 
activation and IP-10 induction (Figures 5B, 5C, 5D). Genetic inactivation of integrase in 
HIVac-1 also maintained the ability to activate DCs and induce IP-10 (Figure S5E). Thus, the 
HIV-1 capsid prevents sensing of the viral cDNA, escaping innate sensing before integration, 
but capsid mutations lead to cDNA-dependent sensing in the cytosol similarly to HIV-2 and 
HIVac-2. 
 
DCs exposed to non-integrative HIVac activate T cells 
The ability of HIVac to stimulate the innate immune response induced by HIV-2 in the 
absence of productive infection prompted us to test if HIVac could activate T cells. First, we 
tested if HIVac could provide functional co-stimulatory activity (Figure S6A). DCs were 
exposed to HIVac-2 particles, leading to DC activation in the absence of infection (Figures 
6A, S6B). In the presence of a limiting dose of an anti-CD3 antibody, added primary naïve 
CD4
+
 T cells proliferated when DCs had been exposed to HIVac-2 (Figures 6A, S6B). This 
proliferation was blocked when DC activation was inhibited by AZT, and it was increased 
when sensing of the virus was enhanced by providing an additional dose of Vpx with VLPs. 
Thus, DC activation by HIVac leads to functional co-stimulation. Next, we tested if 
monocyte-derived DCs obtained from HIV-1-infected subjects were still competent for 
sensing HIVac. We super-infected the DCs with HIV-1 WT or HIVac-1 in the presence of 
Vpx and Raltegravir (Figure S6C). DCs were activated by HIVac-1, but not by the WT virus, 
and HIVac-1 sensing was AZT-sensitive (Figure S6D). Thus, DCs from HIV-1-infected 
subjects remain competent for innate activation by the virus. Since non-infectious HIV 
particles can provide antigen (Buseyne et al., 2001; Manel et al., 2010), we examined if this 
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would increase stimulation of autologous CD8
+
 T cells (Figure S6C). DCs exposed to 
HIVac-1 with Vpx and Raltegravir increased the proliferation of CD8
+
 T cells as compared to 
HIV-1 WT. (Figures 6B, 6C). This effect was blocked by AZT treatment in DCs, indicating 
that it required innate sensing. Thus, HIVac-1 can stimulate CD8
+
 T cells from HIV-1-
infected subjects in the absence of integration. 
 
DC sensing of HIV-1 and HIV-2 requires cGAS 
These results indicate that a cytosolic DNA sensor may be required for HIV sensing. A large 
number of candidate DNA sensors have been proposed in recent years in various cell types 
and models (Paludan and Bowie, 2013). In the transformed human cell line THP-1, the 
sensors cGAS, DDX41 and IFI16 were found to be required for DNA sensing leading to type 
I IFN production (Sun et al., 2013; Unterholzner et al., 2010; Zhang et al., 2011). We 
screened if these sensors could be implicated in HIV sensing by DCs derived from primary 
monocytes using pooled shRNA. Knock-down of DDX41 or IFI16 did not inhibit CD86 
induction by HIVac-2 (Figures S7A, S7B). In contrast, knockdown of cGAS suppressed 
CD86 induction by HIVac-2. We confirmed that the shRNA inhibited by cGAS protein levels 
by transducing individual shRNA (data not shown) and selected two shRNA: shRNA #2, 
which modestly decreased cGAS level, and shRNA #4 which efficiently decreased cGAS 
level (Figure 7A). We stimulated shRNA-transduced DCs with HIV-1, HIV-2, HIVac-2 and 
the soluble RNA molecule poly(I:C) as control. cGAS knock-down prevented induction of 
CD86 by HIV-1, HIV-2 and HIVac-2, but not sensing of poly(I:C) (Figure 7B). Titrated 
infections confirmed that cGAS is required for induction of CD86 by HIV-1, HIV-2 and 
HIVac-2 (Figure 7C). cGAS knock-down also prevented IP-10 production after stimulation 
by HIV-2 and HIVac-2 (Figure S7C). Altogether, these data demonstrate that DC sensing of 
HIV-1 and HIV-2 is mediated by the DNA sensor cGAS. 
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Discussion 
We investigated how human DCs sense HIV-1 and HIV-2. The HIV-1 capsid and its 
interaction with Cyclophilin A were previously found to play an essential role in innate 
sensing of the virus in DCs with Vpx. However, the role of capsid, the actual PAMP and the 
identity of its sensor were not known. By manipulating the interaction between the viral 
capsid and CypA through mutation (HIVac), we were able to dissociate innate sensing from 
productive infection of DCs. Using HIVac as an investigation tool, we report that DC sensing 
of HIV-2 requires reverse transcription of the viral cDNA, but not nuclear entry and 
integration. In contrast to HIV-2, we find that DCs cannot sense HIV-1 before integration 
because the viral capsid prevents cDNA sensing. Capsid-mutated HIV-1 revealed that DCs 
are nonetheless competent for HIV-1 sensing of the viral cDNA before integration. Such 
capsid-mutated particles elicit innate immunity in DCs and activate T cells in the absence of 
viral replication. Finally, we demonstrate that human DCs use the DNA sensor cGAS to sense 
the viral cDNA. Thus, our results establish that, in DCs, the cytosolic viral cDNA is an HIV 
PAMP and that the viral capsid dictates whether this cDNA will escape sensing or will be 
sensed through cGAS. 
 
Various candidate DNA sensors have been proposed in the recent years (Paludan and Bowie, 
2013) that seem to operate differently between human and mouse, between cell types and 
between DNA stimuli (Abe et al., 2013; Brunette et al., 2012; Cavlar et al., 2013; Sun et al., 
2013; Unterholzner et al., 2010; Zhang et al., 2011) and this complexity, that may reflect 
functional redundancy, has not been resolved. In human myeloid dendritic cells, the sensor(s) 
that are required for sensing cytosolic DNA are not yet known. One of the DNA sensors, 
cGAS, synthetizes cyclic GMP-AMP (cGAMP) upon DNA sensing. cGAMP was recently 
detected in DCs infected by HIV-1 in the presence of Vpx (Gao et al., 2013), but whether 
 13 
cGAS or any other DNA sensor is actually required for innate sensing in DCs was not 
evaluated. Using RNAi, we demonstrate that cGAS is essential (non-redundant) for DC 
sensing of HIV.  
 
The demonstration that the wild-type HIV-1 capsid effectively prevents sensing of the viral 
cDNA up to integration provides an explanation for the absence of innate immune response 
up to viral integration in DCs (even in the presence of Vpx) and to the ability of HIV-1-
derived lentiviral vectors to transduce DCs in the absence of innate sensing against the 
lentivector itself (Manel et al., 2010; Satoh and Manel, 2013). Later in the viral cycle, after 
integration and productive infection, DC can sense HIV-1 and this was shown to require 
expression of newly synthesized capsid (Manel et al., 2010; Sunseri et al., 2011). We 
proposed that sensing in this setting implicated unmasking of remaining unintegrated cDNA 
products through interaction with CypA (Manel and Littman, 2011). The demonstration that 
the DNA sensor cGAS is required for HIV-1 sensing argues in favor of this model (Figure 
S8).  
 
How does the HIV-1 capsid prevent sensing of the viral cDNA up to integration? By 
increasing the capsid affinity for CypA through mutations, we find that the cDNA gets sensed 
in the absence of integration (Figure S8). This suggests that the HIV-1 capsid has evolved an 
optimal interaction with CypA that allows cell infection while masking innate sensing of the 
cDNA up to integration (Figure S8). In contrast, wild-type HIV-2 simultaneously infects the 
DCs and triggers innate sensing of its cDNA before integration (Figure S8). This suggests 
that the HIV-2 capsid accommodates a flexible conformation that can both unmask the cDNA 
in the cytosol leading to sensing and also mediate infection. HIV-2 seems to achieve this 
flexibility through a minimal interaction of its capsid with CypA. Nonetheless, HIV-2 is 
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amenable to increased affinity for CypA through mutation (HIVac-2 capsid), leading to 
sensing in the absence of infection, like HIVac-1. The natural balance between infection and 
innate sensing in HIV-2 may contribute to the reduced pathogenicity of this virus, while the 
ability of HIV-1 to prevent sensing of its cDNA may contribute to its immune escape. 
 
Three evidences indicate that the sensing is cytosolic. First, 2LTR circles, a hallmark of 
nuclear import, are not significantly detected when DCs respond to HIVac-2. Second, the 
cPPT is not required for innate sensing. Even though the role of the cPPT in nuclear import is 
incompletely understood (Dvorin et al., 2002; Riviere et al., 2010; Zennou et al., 2000), we 
confirmed that in the experimental conditions that we used, disruption of the cPPT reduces 
the abundance 2LTR circles but did not modify the abundance Late RT cDNA, indicative of 
inhibition before or at nuclear import. Finally, we find that cGAS, a cytosolic DNA sensor 
(Sun et al., 2013), is essential for sensing. 
 
DC sensing of HIV cDNA also requires Vpx, which abrogates the SAMHD1 restriction. 
SAMHD1 was previously identified as an AGS-susceptibility gene, a syndrome characterized 
by apparent uncontrolled induction of a type I interferon innate response. SAMHD1 was also 
found to hydrolyze dNTP in cells, and it is thought that SAMHD1 removal increases 
retroviral cDNA levels by replenishment of the dNTP pool (Lahouassa et al., 2012). Our 
results establish the first direct link between the negative regulation of retroviral DNA 
synthesis by SAMHD1 and induction of an innate immune induced by this DNA. 
Interestingly, innate sensing of HIV-1 DNA was reported in cells deficient for TREX1 (Yan 
et al., 2010), another AGS-related gene (Rice et al., 2007). In contrast to sensing in intact 
human DCs, DNA sensing in TREX1-deficient cells occurs in the context of the wild-type 
HIV-1 capsid. Furthermore, TREX1 is a proviral factor (Yan et al., 2009) while SAMHD1 is 
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a restriction factor (Hrecka et al., 2011; Laguette et al., 2011). Overall, while sensing in DCs 
and in TREX1-deficient cells converge on DNA sensing regulated by AGS genes, the viral 
determinants implicated appear to be distinct. 
 
While pathogenesis induced by HIV-1 and HIV-2 is associated with chronic and non-specific 
general immune activation, the virus-specific immune response induced against HIV-2 
correlates with its reduced pathogenicity (Rowland-Jones and Whittle, 2007) and likely 
contributes its anti-pathogenic activity on HIV-1 (Esbjornsson et al., 2012). Furthermore, 
immunization of macaques with a live-attenuated strain of HIV-2 (Putkonen et al., 1995) 
protects against infection with a pathogenic SIVmac strain. This indicates that HIV-2 contains 
inducers of anti-HIV/SIV immunity, which have not been successfully matched in humans by 
non-lentiviral vaccine candidates. Given the central role of dendritic cells in coupling innate 
sensing to induction of adaptive immunity, cytosolic sensing of the HIV-2 cDNA through 
cGAS in DCs likely shapes these anti-HIV-2 immune responses. We find that a similar DC 
sensing can be obtained in the absence of productive infection of the DCs. Capsid-mutated 
HIVac-2 and HIVac-1 can autonomously activate DCs (with Vpx) in the absence of viral 
integration, hence satisfying the definition of a DC adjuvant, and lead to functional co-
stimulation of naïve CD4
+
 T cells and stimulation of primary CD8
+
 T cells from HIV-1-
infected subjects, respectively. These effects on T cells were blocked by inhibition of reverse-
transcription in DCs, demonstrating that innate sensing of the viral cDNA in DCs was 
required. While antigen specificity of the proliferating cells was not examined, previous work 
showed that DCs exposed to non-infectious particles comparable to HIVac-1 induce antigen-
specific response of CD8
+
 T cells (Buseyne et al., 2001; Manel et al., 2010). It will be 
important to determine the immunogenicity of HIVac-1 in relevant animal models, with or 
without additional antigens. Though no adjuvant is effective to date for HIV-1 vaccination, 
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the pathway we described provides several putative advantages. First, HIV-2 is known to 
induce protection against HIV-1 pathogenesis, unlike current adjuvants. Second, the response 
is specific to HIV, unlike generic adjuvants such poly(I:C). Finally, beyond capsid-mutated 
viruses, our results suggest that DC-targeted agonists of the cGAS pathway in the presence of 
antigen may recapitulate this response. Our results hence provide a molecular basis for 
manipulating this response in order to control or reduce pathogenesis in HIV-1 infected 
patients and to induce anti-HIV-1 immunity. 
 
Altogether, we have identified a mechanism of HIV-1 and HIV-2 sensing in DCs, which is 
tightly regulated by the affinity of capsid for CypA and which requires the DNA sensor 
cGAS. Viral capsid mutations can attenuate the virus and favor triggering of this innate 
response. Stimulation of this response in DCs will likely contribute to generating a more 
effective immune response against the virus. 
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Experimental Procedures 
Constructs 
The HIV-1 WT construct was NL4-3 ∆vif∆vpr∆vpu∆env∆nef encoding GFP in nef and the 
HIV-2 WT construct was ROD9 ∆enf∆nef encoding GFP in nef as previously described 
(Manel et al., 2010). HIV-1 IN D116A was previously described (Manel et al., 2010). 
Mutants HIV-1 V86I-IAP91LPA-M96L (HIVac-1) and HIV-2 P86HA (HIVac-2), IN D116A, 
∆Ψ, ∆Vpx, ∆cPPT were generated by overlapping PCR mutagenesis. Combinatory mutations 
were generated by standard molecular biology procedures. In the HIVac-1 D116A 
experiment, a NL4-3 backbone restored for the SL9 class I epitope was used. Corresponding 
mutagenized sequences are listed in Table S1. HIV-2 ∆Ψ was generated by combining two 
previously described packaging signal deletions (Griffin et al., 2001; Poeschla et al., 1998). 
CMV-VSVG, psPAX2, LKO1puro and pSIV3+ were described elsewhere (Manel et al., 
2010). shRNA against IFI16, DDX41 and cGAS (gene MB21D1) were in the LKO.1-puro 
vector (SIGMA) and are listed in Table S2. Human CypA was amplified from cDNA 
generated by reverse transcription of total RNA extracted from PBMCs. In all final 
constructs, the entire DNA fragments originating from the PCR and encompassing the 
restriction sites used for cloning were fully verified by sequencing. Full length human CypA 
and the NTD of HIV-1 (P1IVQ...TSIL151), HIV-2 WT  (P1VQH...TNIL150) and HIVac-2 
(P1VQH...TNIL151) capsids were amplified by PCR and cloned in a pDONOR vector 
(Invitrogen) using the BP Gateway reaction. A TEV cleavage site (DIPTTENLYFQG) was 
added to the N-terminus of each protein. CypA was transferred using the LR Gateway 
reaction into pDEST-His-GST and pDEST-His (pDEST17) and the capsid NTDs were 
transferred using the LR Gateway reaction into pDEST-His-ZZ (Braud et al., 2005). Plasmid 
DNA was purified using with the low endotoxin HiPure plasmid kit (Invitrogen). 
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Recombinant plasmid DNA did not induce dendritic cell maturation, and viral-producing cells 
were washed after DNA transfection.  
 
Cells.  
GHOST (GHOST X4R5), 293FT and HL116 cells were cultured in DMEM, 10% fetal bovine 
serum (FBS) (Gibco), Penicillin-Streptomycin (Gibco). HL116 cells were supplemented with 
2% HAT (Invitrogen). Peripheral blood mononuclear cells were isolated from buffy coats 
from normal human donors using Ficoll-Paque PLUS (GE). Human CD14
+
 cells were 
isolated by a positive selection with anti-human CD14 magnetic beads (Miltenyi). Purity was 
checked by flow cytometry using an anti-CD14 antibody (antibodies are listed in Table S3) 
and purity was superior to 99%. CD14
+
 and T cells were cultured in RPMI medium, 10% FBS 
(Biowest), Penicillin-Streptomicin, Gentamicin (50 µg/ml, Gibco) and HEPES (Gibco) in the 
presence of recombinant human GM-CSF (Miltenyi) at 10 ng/ml and IL-4 (Miltenyi) at 50 
ng/ml. Fresh media was added at day 3, and cells were stimulated or infected at day 4. Human 
naïve CD4
+
 T cells were sorted by positive selection with anti-human CD4 magnetic beads 
(Miltenyi) followed by sorting on a BD FACSAria IIIu as CD4
+
CD8ß
–
CD27
+
CD45RO
–
. 
 
Virus production. 
Viral particles were produced by transfection of 293FT cells in 6-well plates with 3 g DNA 
and 8 l TransIT-293 (Mirus Bio) per well; for VSV-G pseudotyped SIVmac VLPs, 0.4 g 
CMV-VSVG and 2.6 g pSIV3+; for HIV-1 or HIV-2 VSV-G pseudotyped viruses, 0.4 g 
CMV-VSVG and 2.6 g HIV DNA; for shRNA vectors, 0.4 µg CMV-VSV-G, 1 µg psPAX2 
and 1.6 µg LKO1puro-derived shRNA or pTRIP vector. One day after transfection, media 
was removed, cells were washed out once and fresh media was added. Viral supernatants 
were harvested one day later, filtered at 0.45 M, aliquoted and frozen at -80°C. Viral titers 
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were measured on GHOST cell titration as previously described (Manel et al., 2010). RT 
activity in viral supernatants was measured using either a colorimetric kit containing HIV-1 
RT as a standard (Roche) or using the SG-PERT assay (Pizzato et al., 2009) using M-MuLV 
RT (Finnzyme) as a standard (1 pg/ml of HIV-1 RT standard corresponds to 185 µU/ml in the 
SG-PERT assay). Viral supernatants did not induce dendritic cell activation in the absence 
infection. 
 
Infections. 
At day 4 of MDDC differentiation, cells were harvested, counted and resuspended in fresh 
media at a concentration of one million per ml with 5 µg/ml polybrene, GM-CSF and IL-4, 
and 100 l was aliquoted in round-bottomed 96-well plates. For infection, 50 µl of media or 
SIVmac VLPs were first added. One-hundred microlitres of media or dilutions of viral 
supernatants. Azidothymidine (AZT, SIGMA) or Raltegravir (RAL, Euromedex) were added 
respectively at 24 µM and 20 µM. For type I IFN neutralization, a cocktail containing 6 µg/ml 
recombinant B18R (eBioscience), 1.2 µg/ml monoclonal anti-IFNα (eBioscience), 1.2 µg/ml 
monoclonal anti-IFNß (eBioscience), 1.2 µg/ml monoclonal anti-IFNß (Millipore) and 0.6 
µg/ml monoclonal anti-IFNAR2 (Millipore) were added. 48 hours after infection, cell culture 
supernatants were harvested and ultraviolet-irradiated to inactivate free virus. Supernatants 
were subsequently used for a quantitative bioassay for IFNs or IP-10 quantification. Cell-
surface staining of CD86 (eBioscience) was also performed 48 h after exposure and analyzed 
on a BD Accuri C6 or a BD FACSVerse flow cytometer. Stimulation and DCs activation 
were positively controlled by treatment with high molecular weight poly(I:C) (Invivogen). 
 
Sensors knock-down 
For screening of the sensors, fresh monocytes were co-transduced with a control empty vector 
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LKO.1-puro or a pool of five shRNA vectors in LKO.1-puro against IFI16, DDX41 or cGAS 
(SIGMA) as previously described (Manel et al., 2010; Satoh and Manel, 2013). Knock-down 
efficiency was measured by quantitative PCR on day 4 samples. For validation experiments, 
fresh monocytes were transduced with an empty vector, a shRNA vector targeting LacZ or 
individual shRNA vectors targeting cGAS. Puromycin was added at day 2 (2 ng/ml). At day 
4, DCs were harvested, counted, seeded at 0.5 million per ml in 96-well U bottom plate as 
described above and infected or stimulated in 200 µl of final volume. Surface CD86 
expression and soluble IP-10 production were measured at day 6. Knock-down efficiency was 
measured by quantitative PCR at day 4 and/or western blotting at day 6. For CD86 
expression, donors for which the background of CD86 expression was higher than 20% in 
control samples, or for which the highest dose of stimulation of control shRNA samples did 
not show an induction of at least 20% of CD86-positive cells were excluded from the 
analysis. 
 
Quantitative bioassay for IFNs. 
Supernatants were assayed for IFN activity using the HL116 cell line, which carries a 
luciferase reporter controlled by the IFN-inducible 6-16 promoter, as previously described 
(Uze et al., 1994). In brief, the reporter cells were exposed to cell culture supernatants for 5 h 
and assayed for luciferase activities (Promega), which were then translated to IFN activities 
by using a standard curve generated from a serial dilution of human IFNalpha-2a 
(ImmunoTools). 
 
IP-10 protein quantification 
IP-10 concentration was measured on pure or 10-fold dilutions (controls and HIV infection) 
or 100-fold dilutions (poly(I:C)) of supernatants from infected DCs. IP-10 concentration was 
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measured using a Human IP-10 cytometric assay (BD) according to manufacturer's protocol. 
Data was acquired on a BD FACSVerse (BD) and analyzed in FCAP Array (BD). 
 
HIV-2 Real-time PCR. 
Total cellular DNA was harvested using a Nucleospin Tissue kit (Machery-Nagel). Real-time 
PCR analysis was adapted from (Brussel and Sonigo, 2003) and performed in a Roche 
LightCycler 480 using Roche 480 SYBR Green I master reagent in 20 µl final volume per 
well according to manufacturer specifications. Each sample was measured in triplicate for all 
primers. For beta-globin, primers were bglobin-f CCCTTGGACCCAGAGGTTCT (SEQ ID 
No:43) and bglobin-r CGAGCACTTTCTTGCCATGA (SEQ ID No:44). For Late RT, 
primers were hiv2-3'U3-fwd GAAGGGATGTTTTACCATTTAGTTA (SEQ ID No:45) and 
hiv2-psi-rev GTTCCAAGACTTCTCAGTCTTCTTC (SEQ ID NO:46). For 2LTR, primers 
were hiv2-3'U3-rev TAACTAAATGGTAAAACATCCCTTC (SEQ ID NO:47) and hiv2-R-
fwd GTTCTCTCCAGCACTAGCAGGTA (SEQ ID NO:48). For integrated DNA two rounds 
of amplification were performed. For the first round, primers were alu1 
GCCTCCCAAAGTGCTGGGATTACAG (SEQ ID NO:49) and hiv2-r 
AAGGGTCCTAACAGACCAGGGTCT (SEQ ID NO:50). For the second round, 1 µl of 
first-round reaction was used as template, and primers were hiv2-f2 
GCAGGTAGAGCCTGGGTGTTC (SEQ ID NO:51) and hiv2-r2 
CAGGCGGCGACTAGGAGAGAT (SEQ ID NO:52). Cycling conditions were 1x 95°C 5'; 
35x 95°C 10"-50°C 20"-72°C 30". Relative concentrations of Late RT, 2LTR and integrated 
viral DNA were calculated relative to beta-globin using the ∆Ct method. 
 
Naïve T cell proliferation assay 
 22 
Sorted resting naïve CD4
+
 T cells were stained with a Cell Proliferation Dye (CPD670, 
eBioscience). 2x10
4
 resting T cells were co-cultured with 4x10
3
 autologous infected DCs 
without cytokines in 96-well U bottom plates. Ten-fold dilutions of anti-CD3 antibody (from 
10 pg/ml to 100 ng/ml) or no antibody were added to replicate wells. At day 4 and day 5 post-
stimulation, an aliquot of the cells was fixed and analyzed by flow cytometry on a BD 
FACSVerse. The optimal costimulation-dependent concentrations of anti-CD3 were 100 or 10 
pg/ml depending of the donor. 
 
Stimulation of CD8
+
 T cells from HIV-1-infected individuals 
Blood samples were collected from HIV-1-positive subjects followed in the department of 
clinical immunology of Henri Mondor Hospital, Créteil, France (Table S4). Approval and 
written informed consent from all subjects were obtained before study initiation. The study 
was approved by the ethical committee CCP IX Ile de France, Henri Mondor Hospital, 
Créteil, France. Fresh peripheral blood mononuclear cells were isolated from blood patients. 
Monocytes were isolated by a positive selection with anti-human CD14 magnetic beads 
(Miltenyi) and differentiated in DCs for 3 days. The CD14-negative fraction was cultured in 
RPMI medium, 10% FBS (Biowest), Penicillin-Streptomicin, Gentamicin (50 µg/ml, Gibco) 
and HEPES (Gibco) in the presence recombinant human IL-2 at 50 U/ml and 25 µM AZT or 
in X-VIVO 20 (LONZA), Penicillin-Streptomicin in the presence recombinant human IL-2 at 
50 U/ml, 10 ng/ml recombinant human IL-7 (Miltenyi) and 25 µM AZT. At day 3, DCs were 
super-infected with VSV-G-pseudotyped HIV-1 or HIVac-1 in the presence of SIVmac VLPs, 
20 µM Raltegravir and 25 µM AZT. At day 4, autologous total CD8
+
 T cells were isolated 
from the CD14-negative fraction in culture by a positive selection with anti-human CD8 
magnetic beads (Miltenyi). Sorted CD8
+
 T cells were stained with a Cell Proliferation Dye 
(CPD670, eBioscience). 5x10
4
 DCs were infected and co-cultured one day after with 10
5
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CD8
+
 T cells in 250 µl in 96-well round bottom plates. In some wells, Staphylococcal 
Enterotoxin B was added at 1 µg/ml (Toxin Technology). At day 5 of DC differentiation (day 
1 of co-culture), CD86 and GFP expression was analyzed in DCs from replicate wells in the 
absence of T cells. At day 2 of co-culture, IL-2 was added in at 20 U/ml and at day 5 of 
coculture, a half of the coculture was processed for staining and the other half was kept in 
fresh medium with IL-2 at 20 U/ml for 2 more days and processed for staining at day 7 of co-
culture. Cells were stained with a viability dye (LIVE/DEAD Aqua, Invitrogen) and with anti-
CD8-PE-Cy5.5 and anti-CD4-eFluor-450. Cells were fixed and analyzed on BD FACSVerse.  
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Figure Legends 
Figure 1 Modulation of HIV-2 capsid affinity for Cyclophilin A, a host factor implicated in 
innate sensing by dendritic cells 
(A) Alignment of the CypA-binding loops of HIV-1 and HIV-2 capsids. H87A88 and P90 in 
HIV-1, and P86 and P88 in HIV-2 are indicated in bold. 
(B) Sequence of the putative HIV-2 affine capsid, HIVac-2 (HIV-2 P86HA mutation), same 
region as in (A). 
(C) The structure of the HIV-2 capsid N-terminal domain (red, PDB 2WLV) is aligned on the 
HIV-1 capsid NTD bound to CypA (respectively blue and gray, PDB 1AK4). 
(D) Magnification of the CypA catalytic site bound to HIV-1 (respectively gray and blue, 
PDB 1AK4) or HIV-2 capsids (red, PDB 2WLV). The two residues H87A88 in HIV-1 capsid 
position the proline substrate to interact with H125 and R55 in CypA. In HIV-2, P86 induces 
a distortion in the loop that prevents these interactions. 
(E) The P86HA mutation in HIVac-2 leads to CypA incorporation in viral particles. Left, 
protein expression in virus-producing cells. HIV-1, HIV-2 or HIVac-2 viral proteins were 
analyzed by western blotting against Gag/Capsid, CypA and actin. Right, viral particles were 
analyzed by western blotting against Gag/Capsid and CypA. 
 
Figure 2 Dendritic cells sense HIVac-2 in the absence of infection. 
(A) GFP and CD86 expression in MDDCs 48 hours after infection with HIV-2 WT or HIVac-
2 encoding GFP in Nef and pseudotyped with VSV-G in the presence of SIVmac VLPs. 
(B) Dose-response expression of GFP and CD86 as in (A) (n=7). 
(C) Type I IFN production by MDDCs infected with VSV-G pseudotyped HIV-2 WT or 
HIVac-2, or treated with poly(I:C) (pIC) for 48 hours. (n=7). 
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(D) IP-10 production (n=4; paired t-test on log-transformed data) by MDDCs infected with 
VSV-G pseudotyped HIV-2 WT or HIVac-2 in the presence of SIVmac VLPs, or treated with 
poly(I:C) (pIC) for 48 hours. Dilution factors of the input viral inoculum are indicated. 
 
Figure 3 Dendritic cells sensing of HIV-2 requires a viral cDNA but integration is 
dispensable. 
(A) Principles of the experiments. Left, mutations introduced in HIV-2. Right, early steps of 
the HIV replication cycle affected by the mutation (∆Ψ, ∆Vpx, IN D116A) or the drugs 
(AZT, RAL). 
 (B) GFP and CD86 expression in MDDCs infected with HIV-2 WT or HIVac-2 in the 
absence of presence of AZT or RAL and in the presence of SIVmac VLPs.  
(C) Dose-response expression of CD86 as in (B) (n=4). 
(D) GFP and CD86 expression in MDDCs infected with HIV-2 WT or HIVac-2 with or 
without a mutation in the catalytic site of integrase (IN D116A) in the presence of SIVmac 
VLPs. 
(E) Dose-response expression of CD86 as in (D) (n=6). 
 
Figure 4 Dendritic cells sense HIV-2 viral cDNA in the cytosol. 
(A) Principles of the experiments. Left, mutations introduced in HIV-2. Right, the viral DNA 
species detected by the assay (Late RT, 2LTR circles and Integrated) and the steps inhibited 
by the drugs (AZT, RAL) and the mutation (∆cPPT). 
(B) Quantification of Late RT, 2LTR circles and integrated viral cDNA products 24 hours 
after infection of DCs with HIV-2 WT or HIVac-2 in the presence of SIVmac VLPs. Cells 
were treated with AZT or Raltegravir (RAL) (n=3; representative data for 1 donor is shown). 
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Red arrows indicate the absence of 2LTR-circles and integrated DNA after infection by 
HIVac-2. 
 (C) GFP and (D) CD86 expression in DCs infected with HIV-2 or HIVac-2 that is wild-type 
or mutated cPPT, in the presence of SIVmac VLPs (n=4). 
 
Figure 5 Dendritic cells are competent for sensing of HIV-1 in the absence of infection but 
the wild-type viral capsid prevents innate sensing of the cDNA up to integration. 
(A) Alignment of the CypA-binding loops of HIV-1 WT, HIV-2 WT, HIVac-2 and HIVac-1 
capsids. 
(B) GFP and CD86 expression in DCs infected with HIV-1 WT or HIVac-1. Cells were 
treated or not with Raltegravir (RAL) at the time of infection. SIVmac VLPs were added to 
provide Vpx. 
(C) Dose-response of CD86 expression as in (B) (n=5). 
(D) IP-10 (CXCL10) production by DCs infected with HIV-1 WT or HIVac-1 or treated with 
poly(I:C) (pIC) for 48 hours, in the absence or the presence of Vpx-containing SIVmac VLPs 
or Raltegravir (RAL) (n=5; paired t-test on log transformed data). 
 
Figure 6 Dendritic cells exposed to HIVac stimulate adaptive immunity 
(A) Induction of costimulatory functions by HIVac-2. Expression of CD86 in DCs and 
proliferation of primary naïve CD4
+
 T cells as shown by dilution of a Cell Proliferation Dye 
(CPD). DCs were initially infected or not with HIVac-2. AZT was added to block cDNA 
synthesis and SIVmac VLPs were added to increase the dose of Vpx protein. 
(B) Proliferation of CD8
+
 T cells from HIV-1-infected individuals after co-culture with 
autologous DCs infected super-infected by HIV-1 WT or HIVac-1 in the presence of Vpx-
containing SIVmac VLPs and Raltegravir (RAL), with or with AZT (n=6, except with AZT 
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n=4). Cells were gated by structure, size and LIVE/DEAD. Representative plots at day 7 are 
shown. 
(C) Quantification of CD8
+
 T cell proliferation as in (B) measured at day 5 and day 7 (n=6, 
except with AZT n=4). Proliferating cells were gated by structure, size and LIVE/DEAD and 
as CD4
–
CD8
+
CPD
low
. 
 
Figure 7 cGAS is essential for dendritic cell sensing of HIV 
 (A) cGAS protein levels after RNAi, at day 6 after shRNA transduction in monocytes and 
differentiation in DCs. One representative donor is shown. 
(B) Expression of CD86 and GFP in DCs transduced with a control shRNA against LacZ or a 
shRNA against cGAS and subsequently infected with HIV-1, HIV-2, HIVac-2 or stimulated 
with poly(I:C) (10 µg/ml). Of note, the shRNA transduction procedure at day 0 includes 
addition of Vpx-containing VLPs, which abrogates the SAMHD1 restriction for HIV-1 
infection at day 4. 
(C) Dose-response of CD86 in DCs transduced with shRNA as in (B) and infected with HIV-
1, HIV-2, HIVac-2 (n=3). 
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Supplementary Figure Legends 
Supplementary Figure 1 
(A) Ratios of CypA over capsid in viral particles, quantified from Figure 1E. Ratios were 
normalized to HIV-1. 
(B) Integrity and purity of the recombinant proteins. GST-CypA, HIV-1 WT or HIV-2 WT 
CA NTD and HIVac-2 CA NTD proteins were purified after expression in bacteria. Purified 
proteins were analyzed by SDS-PAGE followed by Coomassie dye staining. 
(C) GST-CypA and CA NTD (HIV-1 WT, HIV-2 WT or HIVac-2) were mixed and incubated 
as indicated. CsA was added when noted. GST pull-down was performed to isolate the GST-
CypA-associated fraction. Flow through fraction were recovered and analyzed by SDS-PAGE 
followed by Coomassie dye staining (Top panel). After GSH elution, the GST-CypA-
associated proteins were analyzed by SDS-PAGE followed silver staining (Bottom panel). 
(D) Interaction between CypA and recombinant N-terminal domains of HIV-1, HIV-2 and 
HIVac-2 capsids, measured by microscale thermopheresis (n=3, one representative 
experiment is shown). 
 
Supplementary Figure 2 
(A) GFP and CD86 expression in MDDCs 48 hours after infection with HIV-2 WT or HIVac-
2. Dose-response expression of GFP and CD86 in the presence or the absence of SIVmac 
VLPs (n=7). 
(B) GFP and CD86 expression and IP-10 production in MDDCs 48 hours after infection with 
HIV-2 WT or HIVac-2, with or without a type I IFN neutralization cocktail. For HIV-2 and 
HIVac-2, the volume of virus per well (µl) is indicated. Four individual donors are shown. 
The dashed line indicates the limit of sensitivity of the standard curve. 
 
 3 
Supplementary Figure 3 
(A) Detection of Gag/CA and Vpx in viral particles of HIV-2 WT or HIVac-2 that have a 
catalytic mutation in integrase (IN D116A) or that have a mutation in the viral RNA 
encapsidation signal (∆Ψ). 
(B) GFP and (C) CD86 expression in MDDCs infected with HIV-2 WT or HIVac-2 with or 
without a mutation in the viral RNA encapsidation signal (n=3). 
(D) GFP and CD86 expression in MDDCs infected with HIV-2 ∆Vpx or HIVac-2 ∆Vpx, with 
or without rescue with SIVmac VLPs.  
 
Supplementary Figure 4 
(A) Detection of Gag/CA, Vpx and CypA in viral particles of HIV-2 WT or HIVac-2 with or 
without a mutation in the cPPT (∆cPPT). 
(B) Quantification of Late RT, 2LTR and integrated viral cDNA products at 48 hours in DCs 
infected with HIV-2 WT or HIVac-2 that are also mutated in the cPPT (n=4, paired t-test on 
log-transformed data). 
 
Supplementary Figure 5 
(A) HIVac-1 particles incorporate more CypA than HIV-1 WT. Left, protein expression in 
virus-producing cells. HIV-1 or HIVac-1 viral proteins were analyzed by western blotting 
against Gag/Capsid, CypA and actin. Right, viral particles were analyzed by western blotting 
against Gag/Capsid and CypA. 
(B) Ratios of CypA over capsid in viral particles, quantified from (A) (n=3; paired t-test 
before normalization). Ratios were normalized to HIV-1 WT. 
(C) Integrity and purity of the recombinant HIV-1 WT CA NTD and HIVac-1 CA NTD 
proteins. Purified proteins were analyzed by SDS-PAGE followed by Coomassie dye staining. 
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(D) Interaction between CypA and recombinant HIV-1 WT CA NTD and HIVac-1 CA NTD 
proteins, measured by microscale thermopheresis (n=3, one representative experiment is 
shown, values are averages of the 3 experiments). 
(E) GFP and CD86 expression and IP-10 production in DCs infected with HIV-1 WT, HIV-1 
IN D116A, HIVac-1, HIVac-1 IN D116A, with of without Vpx or AZT (n=6). Cells were 
infected with similar amounts of particles based on RT activity. The dashed line indicates the 
limit of sensitivity of the standard curve. 
 
Supplementary Figure 6 
(A) Induction of costimulatory functions by HIVac-2, principle and timeline of the assay. 
(B) Quantification of CD86 and GFP expression in DCs at day 0 and of the proportion of T 
cells that divided at day 4 (total or more than one division) (n=4). 
(C) Activation of dendritic cells and stimulation of CD8
+
 T cells from HIV-1-infected 
subjects, principle and timeline of the experiment. 
(D) Expression of GFP and CD86 in DCs super-infected by HIV-1 WT or HIVac-1 in the 
presence of Vpx-containing SIVmac VLPs and Raltegravir (RAL), with or with AZT (n=6, 
except with AZT n=4). 
 
Supplementary Figure 7 
(A) Expression of cGAS, DDX41 and IFI16 measure by RT-qPCR at day 4 in DCs 
transduced with a pool of 5 shRNAs or an empty vector. 
(B) CD86 expression in DCs transduced as in (A) and infected with HIVac-2. 
(C) IP-10 production at day 6, in DCs transduced at day 0 with an empty vector, a control 
shRNA vector against LacZ or shRNA vectors #2 or #4 against cGAS and infected at day 4 
with HIV-2 or HIVac-2. 
 5 
 
Supplementary Figure 8 Model for the capsid-dependent cDNA sensing of HIV-2 or HIV-1 
+ Vpx by dendritic cells. 
 6 
Supplementary Tables 
 
Supplementary Table 1 Mutagenized sequences used in the study. 
 
Backbone Mutation Original DNA sequence Mutagenized sequence 
HIV-1 V86I-IAP91LPA-
M96L (HIVac-1) 
CAT CCA GTG CAT GCA GGG CCT 
ATT GCA CCA GGC CAG ATG  
CAT CCA ATC CAT GCA GGG CCT 
CTT CCA GCA GGC CAG CTG  
HIV-2 P86HA (HIVac-2) CAT CCA ATA CCA GGC CCC TTA CAT CCA ATA CAT GCA GGC CCC 
TTA 
HIV-2 D116A TTG CAT ACA GAT AAT GGT GCC  TTG CAT ACA GCT AAT GGT GCC 
HIV-2 ∆Ψ GCG GCA GGA ACA AAC CAC GAC 
GGA GTG CTC CTA GAA AGG CGC 
GGG CCG AGG TAC CAA AGG CAG 
CGT GTG GAG CGG GAG GAG AAG 
AGG CCT CCG GGT GAA GGT AAG 
TAC CTA CAC CAA AAA CTG TAG 
CCG AAA GGG CTT GCT ATC CTA 
CCT TTA GAC AGG TAG AAG ATT 
GTG GGA GAT GGG  
GCG GCA GGA::GCG CGG GCC GAG 
GTA CCA AAG GCA GCG TGT GGA 
GCG GGA GGA GAA GAG GCC TCC 
GGG TGA AGG TAA GTA CCT A::GA 
TGG GC 
HIV-2  ∆Vpx TGC AAC AAA ATG ACA GAC CC TGC AAC AAA ACG ACA GAC CC 
HIV-2 ∆cPPT ATG GCA GTT CAT TGC ATG AAT TTT 
AAA AGA AGG GGG GGA ATA GGG  
ATG GCA GTT CAT TGC ATG AAc TTC 
AAG CGC CGC GGT GGT ATA GGG  
 
 
Supplementary Table 2 shRNA used in the study. 
 
Gene shRNA identifier TRC identifier Target sequence 
DDX41 #1 TRCN0000001267 GCCACTACCTTCATCAACAAA 
DDX41 #2 TRCN0000001268 GAGGAGATTGAGAACTATGTA 
DDX41 #3 TRCN0000001269 CCATCCAGCACGTCATCAATT 
DDX41 #4 TRCN0000001270 CGCCACTACCTTCATCAACAA 
DDX41 #5 TRCN0000001271 AGACCAGGAGGAACGGACTAA 
IFI16 #1 TRCN0000019079 GCAAATTATGTTTGCCGCAAT 
IFI16 #2 TRCN0000019080 GACAGGACAATGTCACAATAT 
IFI16 #3 TRCN0000019081 GTCAGGTAACTCCCAGAAGAA 
IFI16 #4 TRCN0000019082 CCAAAGAAGATCATTGCCATA 
IFI16 #5 TRCN0000019083 CTGATTCAAGTATGGAAACTT 
MB21D1 #1 TRCN0000148226 GAAGAGAAATGTTGCAGGAAA 
MB21D1 #2 TRCN0000148605 CAGCTTCTAAGATGCTGTCAA 
MB21D1 #3 TRCN0000149811 GCTTTGATAACTGCGTGACAT 
MB21D1 #4 TRCN0000149984 CAACTACGACTAAAGCCATTT 
MB21D1 #5 TRCN0000150010 CCTGCTGTAACACTTCTTATT 
 
 
 
Supplementary Table 3 Antibodies used in the study. 
 
Antigen Source Clone or name 
CD86 eBioscience IT2.2 
CD3 eBioscience OKT3 
CD14 eBioscience 61D3 
CD8ß  Coulter 2ST8.5H7 
CD8 BD RPA-T8 
CD4  Invitrogen S3.5 
CD4 eBioscience RPA-T4 
CD45RO  BD UCHL1 
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Supplementary Table 4 Characteristics of the HIV-1 patients. Values are indicates as mean 
and range. 
 Characteristics 
Number 6 
Age (year) 40.6 (21-56) 
Male/Female 4/2 
Infection duration (years) 14 (4-23) 
Treatment duration (years) 6,9 (0.5-20.5) 
CD4 nadir (cells/mm
3
) 218 (5-350) 
VL baseline, copies/mL 
1
 120.000 (2640-20600) 
CD4 (cells/mm
3
)
 2
 547 (274 – 950) 
CD8 (cells/mm
3
)
 2
 901 (409-1510) 
CD4/CD8 ratio
2
 0.75 (0.19 -1.12) 
1
 at treatment initiation 
2
 at the entry in the study 
 
 
 
Supplementary Table 5 Real-time quantitative PCR primers used in the study 
 
Primer name Sequence 
DDX41qPCR-F GCGACAGATGTCTAGGCTGA 
DDX41qPCR-R CATGTCCGTGAAAGAGCAGA 
ifi16-2068-f TTGTGGCTGATGTGAATGCTGACCG 
CD27 BD M-T271 
Gag/capsid The following reagent was obtained through 
the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: 
HIV-1 p24 Hybridoma (183-H12-5C) from Dr. 
Bruce Chesebro. 
183-H12-5C 
Vpx The following reagent was obtained through 
the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: 
HIV-2 Vpx Hybridoma (6D2.6) from Dr. John 
C. Kappes. 
6D2.6 
Actin Millipore C4 
CypA Wes Sundquist lab UT96 
IFNα eBioscience EBI-1 
IFNß eBioscience A1 
IFNß Millipore A1 
IFNAR2 Millipore MMHAR-2 
cGAS SIGMA HPA031700 
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ifi16-2414-r CCTGGTCTTGATGACCTTGATGTGAC 
cGASqPCR-F AAGGATAGCCGCCATGTTTC 
cGASqPCR-R TGGCTTTCAGCAAAAGTTGG 
bactin737f GGACTTCGAGCAAGAGATGG 
bactin970r AGCACTGTGTTGGCGTACAG 
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Supplementary Methods 
 
Recombinant protein expression and purification 
Protein-expression vectors were transformed in E. Coli BL21 Star (DE3) (Invitrogen). 
Bacteria were plated on Ampicillin 0.1 µg/ml and Chloramphenicol 34 µg/ml. Single colonies 
were expanded in 2YT media with Ampicillin and Chloramphenicol 34 µg/ml at 37°C 
overnight. Pre-cultures were diluted to OD600 0.05 and expanded up to OD600 0.5. Protein 
expression was induced with IPTG 1 mM for 4 h at 30°C. Cells were washed in PBS and 
frozen. Bacteria were lysed for 1 h at 4°C on a rotating wheel in PBS supplemented with 150 
mM NaCl, 1 mg/ml lysozyme (Sigma), 10 mM MgCl2, 100 µg/ml DNAse I (Roche), 0,5% 
Triton X-100, 15 mM imidazol and protease inhibitors (EDTA-free Complete cocktail, 
Roche). Lysates were clarified by centrifugation for 30 min at 75600 g and 4°C. His-tagged 
proteins were bound to Protino Ni-NTA agarose gel (Macherey-Nagel) for 1 h at 4°C on a 
rotating wheel. Beads were centrifuged for 10 min at 470 g and 4°C, washed two times in 
PBS supplemented with 350 mM NaCl and 15 mM imidazole, and 1 time in 50 mM Tris-HCl 
pH 8. Beads were packed in columns (Machery-Nagel), and proteins were eluted in 50 mM 
Tris-HCl pH 8 with 250 mM imidazol. Proteins were quantified using a Bradford assay (Bio-
Rad) and BSA standards (Pierce). His-ZZ-Capsid NTD proteins were stored at -20°C in 
elution buffer, and His-GST-CypA was stored at -20°C in elution buffer supplemented with 
10% glycerol. Integrity and purity of each protein was analyzed by SDS-PAGE followed by 
Coomassie dye staining (LabSafe GEL Blue). 
 
CA-CypA protein interaction analysis 
Protein-protein interactions were performed with MagneGST Glutathione beads (Promega). 
All the steps were performed at 4°C on ice. The beads were washed two times with 
Binding/Wash buffer (4.2 mM Na2HPO4, 2 mM K2HPO4, 140 mM NaCl, 10 mM KCl) and 
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one time with Binding/Wash buffer supplemented with filtered 0.1% BSA (Euromedex). 
Beads were then saturated in Binding/Wash buffer supplemented with 0.1% BSA and 
incubated on a rotating wheel for one hour.  Protein interaction reactions were performed with 
50 µg His-GST-CypA and 200 µg His-ZZ-Capsid NTD incubated for one hour on a rotating 
wheel. 10 µM CsA (Sigma) was added when noted. Proteins were next incubated with the 
beads for one hour on a wheel. Flow through fractions were isolated. Beads were washed 3 
times in Binding/Wash buffer, with or without CsA. After the last wash, beads were incubated 
15 min with gentle mixing in elution buffer (50 mM reduced glutathione (GSH) pH 7.0-8.0 
(Sigma) in PBS  pH 7.4 (Gibco)). Flowthrough fractions and eluates were analyzed by SDS-
PAGE followed respectively by Coomassie staining and silver stain staining (BioRad 
Dodeca). 
 
Microscale Thermopheresis analysis 
For MST, fresh affinity-purified recombinant His-ZZ-CA-NTD and His-CypA were further 
purified by fast protein liquid chromatography on Äkta systems (GE Healthcare Life 
Sciences). A Superdex 75 10/30 column balanced in PBS was used for the separation. All 
runs were performed at 10°C. Fraction were checked by Coomassis SDS-PAGE, pooled and 
concentrated using Amicon Ultra-4 10K filter units. His-CypA was further labeled with the 
Monolith NT Protein Labeling Kit BLUE according to the recommendations of the 
manufacturer (NanoTemper Technologies). Protein concentrations and protein–dye ratios 
were determined on a NanoDrop 2000 (Thermo Scientific) using extinction coefficient 
predicteds by ProtParam (Artimo et al., 2012). Protein-protein interactions were analyzed by 
MST on a Monolith NT.115 (NanoTemper technologies) using standard capillaries. His-ZZ-
Capsids were 2-fold diluted sixteen times in PBS-Tween 0,05% and a one-to-one volume of 
His-CypA was added to a constant concentration of 500mM final. All measures were 
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performed at 20°C, Laser power at 10% and LED power adjusted between 20 and 50% 
depending on the labeling intensity. All measures were performed in two or three locations 
per capillary, and measures were repeated independently three times. Kd values were 
calculated in the NTAnalysis software (NanoTemper technologies). 
 
Gene expression quantification 
Four days after lentiviral vector transduction, total RNA was extracted from 250,000 MDDCs 
using Nucleospin RNA II kit (Macherey-Nagel). cDNA was synthesized with random 
hexamer from 0.1µg total RNA using SuperScript III Reverse Transcriptase (Invitrogen). 
Real-time qPCR was performed using SYBR Green I Master (Roche). Expression level of 
mRNA was calculated with the standard curve method. The primer sequences are listed in 
Table S5. 
 
Western Blotting 
0.2 to 2 millions cells were lysed in 80 µL of Lysis buffer (50 mM Tris Hcl pH8, 120 mM 
NaCl, 4 mM EDTA, 1% NP40 and 1x EDTA-free protease inhibitors cocktail (Roche)). 
Lysates were cleared by centrifugation at 5500 g for 7 minutes at 4°C. Virus supernatants 
were filtered at 0.45 µm, centrifugated at 16000 g for 1 h 30 min at 4°C. Virus pellets were 
lysed in 15 µl of Lysis buffer. Cellular and viral protein lysates were resolved on 4%-20% 
Biorad precast SDS-PAGE gels and transferred on nitrocellulose membrane. Proteins were 
blotted with antibodies as follow: mouse anti-Gag/capsid; mouse anti-Vpx; mouse anti-actin; 
rabbit anti-CypA. ECL signal was recorded on the ChemiDoc XRS Biorad Imager. Data was 
analyzed and quantified with the Image Lab software (Biorad). 
 
Statistics 
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Statistical analyses were performed in Prism (GraphPad). The paired t-test was used, unless 
indicated otherwise in figure legends. In figures, * p<0.05, ** p<0.01, *** p<0.001, ns=not 
significant. 
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